EP Wealth Advisors LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 18,036 shares of the medical research company’s stock after purchasing an additional 324 shares during the quarter. EP Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $4,402,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Prime Capital Investment Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 396.0% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 620 shares of the medical research company’s stock valued at $151,000 after purchasing an additional 495 shares in the last quarter. Ancora Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $166,000. Atlantic Trust LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $154,000. Capital Guardian Trust Co. bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $189,000. Finally, Summit Financial Group Inc. bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $201,000. Institutional investors and hedge funds own 86.95% of the company’s stock.
Several research analysts recently commented on the stock. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Friday, November 30th. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $250.00 to $275.00 and gave the stock an “overweight” rating in a research note on Monday, September 24th. Goldman Sachs Group lowered shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Monday, September 17th. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $242.00 to $254.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 10th. Finally, Citigroup boosted their price objective on shares of Thermo Fisher Scientific from $260.00 to $280.00 and gave the stock a “buy” rating in a research note on Wednesday, October 10th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $263.64.
In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, December 7th. The shares were sold at an average price of $241.45, for a total transaction of $2,293,775.00. Following the sale, the chief financial officer now owns 44,124 shares of the company’s stock, valued at approximately $10,653,739.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 125,520 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $247.50, for a total transaction of $31,066,200.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 158,127 shares of company stock worth $39,038,285. 0.49% of the stock is owned by insiders.
NYSE TMO opened at $241.27 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.84 and a quick ratio of 1.27. The company has a market cap of $94.95 billion, a P/E ratio of 25.42, a PEG ratio of 1.71 and a beta of 1.09. Thermo Fisher Scientific Inc. has a 52 week low of $188.20 and a 52 week high of $253.91.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 24th. The medical research company reported $2.62 EPS for the quarter, topping the consensus estimate of $2.55 by $0.07. The firm had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.70 billion. Thermo Fisher Scientific had a net margin of 10.75% and a return on equity of 16.49%. Thermo Fisher Scientific’s revenue was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.31 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 11.05 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, January 15th. Shareholders of record on Monday, December 17th will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.28%. The ex-dividend date is Friday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 7.17%.
Thermo Fisher Scientific announced that its board has authorized a stock repurchase program on Friday, September 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 2.1% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.
ILLEGAL ACTIVITY NOTICE: “Thermo Fisher Scientific Inc. (TMO) Shares Bought by EP Wealth Advisors LLC” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/12/13/thermo-fisher-scientific-inc-tmo-shares-bought-by-ep-wealth-advisors-llc.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.